Phase II study of biweekly cetuximab+irinotecan therapy for unresectable colorectal cancer

ABSTRACT: Interventions: biweekly cetuximab Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Colorectal Cancer

PROVIDER: 2626733 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR